As far as immunotherapy is concerned, in the study of Sun et al. (30), the radiomic-based biomarker of tumor-infiltrating CD8 cells was validated in 3 independent cohorts and showed predictive value for tumor response to the anti-PD-1 or anti-PD-L1 therapy. The gene discussed is CD274; the disease is neoplasm.